News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
December 23, 2013
Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability
November 4, 2013
Resverlogix Announces Voting Results
October 4, 2013
Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis
September 3, 2013
Resverlogix Announces a Corporate Update Conference Call & Webcast
August 29, 2013
Resverlogix Closes $1.6 million Private Placement
August 14, 2013
Resverlogix Announces $1.6 million Private Placement
August 12, 2013
Resverlogix to host Conference Call & Webcast with Q&A
June 28, 2013
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
June 27, 2013
Resverlogix Corp. announces completion of spin-out transaction
June 3, 2013
Zenith Epigenetics Corp. commences operations
June 3, 2013
Resverlogix Corp. shareholders approve plan of arrangement
May 28, 2013
Resverlogix Announces Details of Anticipated Distribution of Newco Shares
May 27, 2013
Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of Shareholders
May 1, 2013
Resverlogix Completes Dosing In ASSURE Clinical Trial
April 18, 2013
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
April 8, 2013
Resverlogix Secures Increase to Citibank Loan to $38.8 million
March 11, 2013
Resverlogix comments on steady climb of share price
January 31, 2013